Company: STAA
Filing Date: 2025-10-21
Form Type: PX14A6G
Source: 0001193125-25-244217
Chunk: 3

Company: STAAR SURGICAL CO
Filing Date: 2025-10-21
Form: PX14A6G
Chunk 3
---
 shopped under the current circumstances and while Alcon’s
$28 dollar offer remains outstanding and still scheduled for shareholder approval at a future date. Such a process would be unduly rushed, would occur at the same time as the Company is recovering from setbacks, and would be overseen by certain
directors and officers who are conflicted in light of the Alcon transaction.

If STAAR is to look for additional buyers in the future, it should do so
after the merger agreement with Alcon is ended and in a framework allowing sufficient time for a comprehensive market check and for

2

potential counterparties to conduct due diligence, such as a period of three to six months. A properly run process could invite interest from both strategic buyers (including Alcon, if willing)
and financial sponsors, providing participants with access to data rooms, management presentations, and discussions with distributors and other stakeholders. Directors and officers involved with the process would have the benefit of advice from
independent industry consultants and financial advisors. Directors and officers who would be conflicted in light of the Alcon transaction can and should also recuse themselves from oversight of such a process.

3. Preliminary Net Sales Results for Third Quarter 2025 Support Our Opposition to the Proposed Merger

The recent press release from STAAR of October 20, 2025, announcing preliminary net sales results for the third quarter, underscores a positive trajectory
for the Company, particularly in the critical China market. After adjusting for sales in other geographies, China revenue in the third quarter is estimated at approximately $54.4 million, bringing total China-related revenue for the first three
quarters of 2025 to about $142.6 million when factoring in earlier de-stocking activity.

Contrary to the
claim that demand in China remains soft or will continue to decline, the data suggests the opposite. STAAR’s reported revenue is not a direct representation of end demand, as it is influenced by channel inventory movements and distributor
ordering patterns rather than the pace of actual surgical procedures. When those inventory effects are removed, the underlying picture becomes clear: procedure-level, end-consumer demand in China has remained
strong throughout 2025. The apparent softness in reported sales reflects an intentional and largely completed effort by distributors to normalize inventories, not a contraction in patient demand or physician activity.

Viewed from this “end-demand” perspective, the reconstructed China revenue trajectory provides the
clearest evidence yet of stabilization and renewed momentum. The Company’s investor presentation issued on September